November 2, 2026

Dear Fellow Stockholders,

Our annual meeting of stockholders was held on August 20, 2026. At the meeting, R. Stephen Beatty, Robin L. Carmichael, Richard M. Cohen, William A. Goolsbee and Lawrence Blake Jones were elected to the board of directors to serve for the 2026-2027 term. In addition, the appointment of Baker Tilly (formerly Moss Adams, LLP) as our auditor for fiscal year 2026 was ratified.

Private Placement

On August 25, 2026, we completed a private placement financing generating gross cash proceeds of $2 million. Under the terms of the financing, the Company issued 100,000 shares of common stock to an accredited investor, who is a current stockholder of the Company holding over 50% of the Company's outstanding securities, at a purchase price of $20.00 per share. Under the investment, the investor holds two special rights. First, a one-time discount right to purchase securities in the Company's next qualified financing at 80% of the lowest per-share price paid by any other investor in that round, exercisable at the round's initial closing. Second, weighted-average anti-dilution protection: if the Company's first down-round financing (below the $20.00 per-share reference price) occurs within 36 months of closing, the investor will receive additional "top-up" shares at no cost to offset the lower price. Both rights are one-time only and expire on the earlier of 36 months after the closing date or, with respect to the discount right, the Company's next qualified financing, and, with respect to the anti-dilution protection, the Company's first down-round.

The proceeds will be used primarily to advance Helix BioMedix's lead development program for Xeroderma Pigmentosum (XP), an ultra-rare genetic disease characterized by defective DNA repair mechanisms that leave patients highly vulnerable to ultraviolet (UV) radiation-induced DNA damage and significantly increased skin cancer risk.

Select Q2 2026 Results (unaudited)

In other updates, our (unaudited) second quarter financial results are now available. The total revenue for the second quarter of 2026 was $248,000 compared to $186,000 for the same period in 2025 reflecting increased licensing royalties. Gross profits for the second quarter of 2026 were $248,000 compared to $186,000 for the same period in 2025. Operating expenses for the second quarter of 2026 were ($463,000) compared to ($510,000) for the same period in 2025. The operating loss in the second quarter of 2026 was ($215,000) compared to a loss of ($324,000) in the second quarter of 2025. The Company's non-cash stock expense fluctuates substantially from quarter to quarter. As a result, the Company's management and Board of Directors exclude this expense from our operating expenses in assessing the Company's ongoing performance, which makes such calculation a non-GAAP financial measure. This information is reflected below.

Select Financial Highlights (000's) (unaudited)

Item		***Q2 2026***	***Q2 2025***
Revenue		*$248*	*$186*
Gross Profits		*$248*	*$186*
Operating Expenses		*($463)*	*($510)*
	Excluding Stock Expense	*($463)*	*($509)*
Operating profit (loss)		*($215)*	*($324)*
	Excluding Stock Expense	*($215)*	*($322)*
Cash + A/R – A/P		*$1,383*	*$1,593*

Legacy Peptide Business

Our licensing revenues are royalty-based and, therefore, carry no cost of goods. While royalty payments appear to be "pure profit," we must measure this royalty income against the costs required to support our ongoing patent obligations and the development/production costs required to support our licensing partners and generate new product opportunities. Our licensing activities continue to provide us with an ongoing royalty stream.

We currently have two primary licensed distributors of our peptide technologies into the personal care market. These partners command a strong presence in the marketplace and represent our portal to industry leaders that a small company such as ours could not easily and quickly access directly.

Rare Disease Program

Rare diseases are classified in the United States as those afflicting fewer than 200,000 individuals. The FDA has established the Orphan Drug Program to help incentivize companies to pursue drugs for the treatment of rare diseases. The Orphan Drug Act includes a number of incentives, currently including expanded access to the Investigational New Drug (IND) Program, grants for drug development, a waiver of user

fees charged under the Prescription Drug User Fee Act (PDUFA), fast-track approvals, tax credits, and 7-year market exclusivity for an approved orphan drug.

Helix BioMedix is developing HB4208 for treatment of the rare disease, Xeroderma Pigmentosum (XP). XP is an inherited skin disorder characterized by hypersensitivity to the sun and ultraviolet (UV) rays. Individuals with XP are highly susceptible to DNA damage caused by UV light due to either lack of the normal repair mechanism or defective repair pathways to manage the damage. XP is a devastating disease for which there is currently no known cure and that significantly impacts both quality of life and life expectancy.

HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on repair pathways necessary to prevent cancerous mutations and maintain skin homeostasis. In early proof of concept work, the first-generation DDR enzyme demonstrated positive results to modulate UV-induced DNA damage and reduce skin lesions in an animal model. Our preclinical program has focused on refinements in the structure of the protein enzyme to improve stability and manufacturing yields. Additionally, we implemented a study in disease-state XPA mice that looked at histological changes in UV exposed skin which provided additional proof of concept.

In mid-June 2025, we submitted a request to the FDA for an INTERACT Meeting. INTERACT, or an **In**itial **T**argeted **E**ngagement for **R**egulatory **A**dvice on **C**BER/CDER ProducTs, is a meeting at a specific time early in product development. The appropriate timing for an INTERACT meeting is when a sponsor has identified the investigational product to be evaluated in a clinical study and conducted some preliminary preclinical proof-of-concept studies with the intended investigational product but has not yet designed and conducted definitive toxicology studies. Following our INTERACT meeting, we received a response from the FDA indicating that our current preclinical work was "reasonable" and that we could continue our plan to pursue a small microdosing study. We are currently working on developing the clinical protocol and supporting assays and obtaining the necessary materials to be able to conduct the study. Although we intend to proceed with a small microdosing study, there is no assurance that this study will yield beneficial or helpful results, that the FDA will allow us to move forward with any subsequent studies, or that any such studies will ultimately lead to a commercialized product.

Later in November, I will be attending an XP patient conference to meet with families and provide an update on our work.

Patents
Helix BioMedix has a significant patent portfolio with over 180 patents worldwide. These patents expire in a range from mid-2027 to mid-2034.

Closing Comments
On behalf of myself and the Board of Directors, I would like to express our sincere gratitude to you all for your loyalty and support. Helix BioMedix is moving forward with high energy and expectations. We are focused on the important tasks ahead of us and we look forward to sharing corporate developments and our preclinical progress with you.

Sincerely,

Robin L. Carmichael
President & Chief Executive Officer
rcarmichael@helixbiomedix.com

* * *

Forward Looking Statements
This document contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development, the feasibility, timing, results and advancement of its rare disease program and planned microdosing study, its regulatory interactions with and submissions to the FDA, the availability and retention of orphan drug designation, market exclusivity and related incentives, its patent portfolio and the duration of patent protection, its licensing arrangements and royalty revenue, the completion, terms and effects of current and future financings, and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital on acceptable terms; the potential dilution to existing stockholders resulting from current and future financings, including any down-round financing that triggers anti-dilution adjustments; the company's dependence on a limited number of licensing partners and the concentration of its royalty-based revenue; the expiration, scope and enforceability of its patents and the resulting impact on licensing revenue; the uncertainty of FDA feedback and future authorizations; the risk that preclinical or clinical results are unfavorable or do not support further development or commercialization; the company's ability to obtain and retain orphan drug designation, market exclusivity and other regulatory incentives; its ability to develop effective drug candidates, enter into revenue generating license agreements, and continue its research and development efforts, including pre-clinical and clinical studies; and general economic conditions. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.